ArticleNature communications2025
Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants.Nature immunology · 2026Article
- Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations.Nature communications · 2026Article
- Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.Biologicals : journal of the International Association of Biological Standardization · 2026Article
- Comparable Neutralizing Antibody Responses Following JN.1 and KP.2-Based COVID-19 Vaccination Suggest Limited Added Value of Minor Strain Updates: A Multicentre Immunogenicity Study.Influenza and other respiratory viruses · 2026Article
- BNT162b2 LP.8.1 early vaccine effectiveness against COVID-19 emergency department, urgent care, and outpatient visits.Nature communications · 2026Article
- Impact of Risk Factor Combinations on Severe COVID-19 Outcomes Among Outpatients.Infectious diseases and therapy · 2026Article
- Article
- RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review.Pharmaceutics · 2026Review
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
- Effectiveness of 2024/25 KP.2 Vaccine Against Outpatient COVID-19 in Canada.Influenza and other respiratory viruses · 2026Article
- Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19.JAMA network open · 2026Article
- Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults.Open forum infectious diseases · 2026Article
- Effectiveness of the 2024-2025 KP.2 COVID-19 vaccines in the United States during long-term follow-up.Nature communications · 2025Article
- Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo.Nature communications · 2025Article
- COVID-19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024-May 2025.Influenza and other respiratory viruses · 2025Article
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.bioRxiv : the preprint server for biology · 2025Article
- Effectiveness of 2024-2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes - IVY Network, 26 Hospitals, September 1, 2024-April 30, 2025.medRxiv : the preprint server for health sciences · 2025Article
- Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.Infectious diseases and therapy · 2025Article
- COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network.Influenza and other respiratory viruses · 2025Article
- Respiratory symptom patterns in healthcare workers in Germany: a prospective study during the SARS-CoV-2 pandemic.Frontiers in public health · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This test-negative case-control study within the US Veterans Affairs Healthcare System aims to estimate early vaccine effectiveness (VE) of the BNT162b2 KP.2 vaccine (2024-2025 formulation) compared to not receiving the KP.2 vaccine against COVID-19 outcomes. The study includes adult patients (age ≥18 years) with an acute respiratory infection (ARI) in hospital, emergency department and urgent care (ED/UC), or outpatient settings between September 5 and November 30, 2024. Separate multivariable logistic regression models compare the odds of receiving BNT162b2 KP.2 vaccine among SARS-CoV-2 positive cases and test-negative controls within each ARI outcome category, while adjusting for potentially confounding variables. Among 44,598 ARI episodes, VE is 68% (42-82%), 57% (46-65%), and 56% (36-69%) against COVID-19-associated hospitalizations, emergency department and urgent care visits, and outpatient visits, respectively. Uptake of updated COVID-19 vaccines is low (3.7%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.